

PRESS RELEASE



September 9, 2019, Lund, Sweden

Immunovia Announces the Agenda for today's Webinar

LUND, SWEDEN - Immunovia today released the agenda for the company's first webinar in Immunovia's IMMray™ PanCan-d Webinar Series (in English), *Differentiating Pancreatic Ductal Adenocarcinoma (PDAC) from individuals with symptoms suggestive of PDAC, including type II diabetes, with ROC AUC values above 0.95*. This webinar series will cover all the development milestones of IMMray™ PanCan-d, Immunovia's launch, and post-launch activities such as the prospective study results and readouts.

The first webinar will air today, September 9th at 18:30 CET. Immediately after the webinar, the Immunovia team will host a live Q&A session. A live webcast of the webinar can be accessed via the following link: <http://livewebcast.net/immunovia/090919>

Event Details:

Immunovia's IMMray™ PanCan-d Webinar Series

Webinar No. 1: *Differentiating Pancreatic Ductal Adenocarcinoma (PDAC) from individuals with symptoms suggestive of PDAC, including type II diabetes, with ROC AUC values above 0.95*

Monday, September 9, 2019 at 18:30 CET

Presenters: Linda Mellby, PhD and Thomas King, MD, PhD, Immunovia

Agenda:

IMMray™ Technology

Linda Mellby, PhD, VP R&D, Immunovia

IMMray™ PanCan-d for detection of early stage (I&II) PDAC - *published in Journal of Clinical Oncology (JCO) Aug 2018*

Linda Mellby, PhD, VP R&D, Immunovia

IMMray™ PanCan-d differentiating PDAC from symptomatic individuals including type II diabetes - *Optimization study results*

Thomas King, MD, PhD, Medical Director, Immunovia

Next steps

Thomas King, MD, PhD, Medical Director, Immunovia

Summary

Thomas King, MD, PhD, Medical Director, Immunovia

About the presenters:**Dr. Linda Mellby, VP Research & Development, Immunovia**

Dr. Mellby received her PhD in Immunotechnology from the Department of Immunotechnology within CREATE Health Translational Cancer Center, Lund University, and a MSc in Chemistry Engineering. Mellby has 15+ years of experience in recombinant antibody microarray technology, the Immunovia platform. Additionally, she has deep knowledge on platform features, technology development, as well as, clinical applications within oncoproteomics and autoimmunity.

Dr. Thomas King, Medical Director, Immunovia, Inc.

Dr. King is a board-certified MD Pathologist with a Ph.D. in Molecular Biology also from Washington University in St. Louis. Dr. King also has extensive experience as a laboratory director in hospital, academic and corporate settings in New England. He has deep expertise in laboratory administration and automation, surgical pathology, and molecular pathology and is currently an Adjunct Associate Professor in the School of Health Professions, Rutgers University.

For more information, please contact:

Julie Silber, Director of Investor Relations, Immunovia

Email: julie.silber@immunovia.com

Tel: +46 7 93 486 277

About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

###